


CANDIDATE:

Bridge to Transplant

for patients under 50 years old

Clinical scenario

Presented to his PCP with complaints of shortness of breath and limitations in daily activities. He was treated for pneumonia. After symptoms worsened, he went to his local ER and was admitted for heart failure (HF). After treating for HF, the Shared Care site referred him to the implanting center for evaluation of the LVAD.

Clinical Presentation

- Limited physical activity and shortness of breath
- EF 10-15%
- Readmitted 3 times within year

LVAD Implant

Device/Indication: HeartMate 3™ LVAD, Bridge to Transplant

LVAD Implant Date: April 4, 2019

Age at Implant: 25 years old

Procedure: Full-Sternotomy

Post-implant: Discharged from hospital 17 days after implantation.


Jermayne

- **29 yr old man**
- **Care Partner:** Keima, spouse
- **Bio/Activity:** Jermayne works as a chef and owns his own food truck. He also enjoys teaching children how to cook. He and his wife, Keima were married in February 2022.

Medical History

Diagnosis: Chronic Myocarditis (Viral Cardiomyopathy)

Medication: Spironolactone, Digoxin, Lisinopril, Entresto, Carvedilol, Lasix

Other Procedures: Defibrillator

HF Classification: NYHA Class IV

Living with LVAD

As a HeartMate LVAD recipient, Jermayne wants you to know:

“You can have a good heart even with a bad heart!”



Abbott
6101 Stoneridge Dr., Pleasanton, CA 94588 USA,
Tel: 1 925 847 8600

cardiovascular.abbott/lvad-patient-case-study-profiles

These testimonials relate an account of an individual's response to the treatment. The patient's account is genuine, typical and documented. However, it does not provide any indication, guide, warranty or guarantee as to the response other persons may have to the treatment. Responses to the treatment discussed can and do vary and are specific to the individual patient.

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

HeartMate 3™ LVAS Indications: The HeartMate 3™ Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in adult and pediatric patients with advanced refractory left ventricular heart failure and with an appropriate body surface area.

HeartMate 3™ LVAS Contraindications: The HeartMate 3 Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy.

HeartMate 3™ LVAS Adverse Events: Adverse events that may be associated with the use of the HeartMate 3 Left Ventricular Assist System are: death, bleeding, cardiac arrhythmia, localized infection, right heart failure, respiratory failure, device malfunctions, driveline infection, renal dysfunction, sepsis, stroke, other neurological event (not stroke-related), hepatic dysfunction,

psychiatric episode, venous thromboembolism, hypertension, arterial non-central nervous system (CNS) thromboembolism, pericardial fluid collection, pump pocket or pseudopocket infection, myocardial infarction, wound dehiscence, hemolysis (not associated with suspected device thrombosis) or pump thrombosis.

™ Indicates a trademark of the Abbott group of companies.
‡ Indicates a third party trademark, which is property of its respective owner.

© 2026 Abbott. All Rights Reserved.

MAT-2515405 v1.0 | Item approved for U.S. use only.